Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 44 news outlets
blogs: 16 blogs
policy: 1 policy source
twitter: 98 X users
patent: 93 patents
facebook: 13 Facebook pages

wikipedia: 10 Wikipedia pages
googleplus: 4 Google+ users
reddit: 8 Redditors
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1571 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 2 policy documents that reference this research output.

Talimogene laherparepvec for treating unresectable metastatic melanoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 09 Aug 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Talimogene laherparepvec for treating unresectable metastatic melanoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 16 Mar 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.